New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia
NCT00342589 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1015
Last updated 2026-05-01
Summary
This study will examine the effectiveness of a new laboratory method for detecting pneumocystis organisms in a salt-water (saline) oral wash. Pneumocystis infection in people with weakened immunity especially patients with HIV infection or cancer, organ transplant recipients and people receiving immune suppressing therapy can cause life-threatening pneumonia. Currently, pneumocystis infection is diagnosed by sputum analysis or bronchoalveolar lavage. For the sputum analysis, patients are induced to produce a sputum sample (liquid discharge from the lung) using a saline mist; however, many hospitals lack the expertise to perform this procedure. The second method, bronchoalveolar lavage, involves inserting a flexible tube into the lung and injecting saline to produce a specimen for diagnosis. This method, however, is time-consuming and can be uncomfortable. New techniques may allow the use of an oral wash to diagnose pneumocystis, even though an oral sample contains far fewer organisms than are obtained with the current methods. This study will examine whether new techniques, such as nucleic acid amplification, may enable a simple oral wash to be used effectively for diagnosis of pneumocystis infection.
Patients 3 years of age and older with weakened immunity who have acute pneumonia may be eligible for this study. In addition, people at increased risk of infection with pneumocystis, including health care professionals, family members of patients, and other patients in health care facilities, may participate.
Participants will have a medical history and review of medical records to determine their health status and determine if they have had recent respiratory problems or documented PCP. They will then provide an oral wash sample. For this procedure, subjects first rinse their mouth well. Then, they vigorously swish 50 milliliters of saline for 5 to 10 seconds and immediately repeat the procedure to provide two specimens. Washes may be requested daily, weekly, monthly, or for a period of time to be specified. Participants will also have two tubes of blood drawn (total of 20 milliliters, or 4 teaspoons) to test for evidence of pneumocystis.
Although no other tests are required for this protocol, participants may be asked to provide optional add'l samples, as follows:
If a sputum or bronchoalveolar lavage sample is required in the course of the patient s clinical mgmt, enough material will be obtained, if possible, for research purposes as well as what is needed for routine care.
An induced sputum sample may be requested just for this protocol. For this procedure, a mask with a saline mist is placed over the face, inducing a cough that, it is hoped, will produce sputum from the lungs.
Conditions
- Pneumocystis Infection
- Infection
- Pneumonia, Pneumocystis
- Lung Disease, Fungal
- Mycoses
Sponsors & Collaborators
-
National Institutes of Health Clinical Center (CC)
collaborator NIH -
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Principal Investigators
-
Joseph A Kovacs, M.D. · National Institute of Allergy and Infectious Diseases (NIAID)
Eligibility
- Min Age
- 3 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1999-09-28
Countries
- United States
Study Locations
More Related Trials
-
An Efficacy and Safety Study of Itraconazole Sequential Therapy (Intravenous Injection Followed by Oral Solution) in Invasive Pulmonary Fungal Infections
NCT01823289 ·Status: COMPLETED ·Phase: PHASE4
-
Voriconazole to Treat Fungal Infections
NCT00001940 ·Status: COMPLETED ·Phase: PHASE3
-
Breath Analysis for the Detection of Invasive Fungal Infections
NCT06537726 ·Status: RECRUITING
-
An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections
NCT00001810 ·Status: COMPLETED ·Phase: PHASE3
-
Characterizing Diversity and Antifungal Resistance in Immunocompromised ICU Patients With Respiratory Tract Infections
NCT06387667 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Exhaled Breath Analysis in the Early Detection of Aspergillosis
NCT02106117 ·Status: COMPLETED
-
Fungal Infection Susceptibility
NCT00001352 ·Status: RECRUITING
-
The Impact of Rapid Diagnostic Methods in the Diagnosis of Fungal Infections in Intensive Care Units of Assiut University Hospital
NCT05876962 ·Status: UNKNOWN
-
Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections
NCT03827694 ·Status: RECRUITING
-
Open Label Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P00041)
NCT00034658 ·Status: COMPLETED ·Phase: PHASE3
-
A Multicenter, Prospective, Randomized, Double-Blind Clinical Trial Comparing Itraconazole Oral Solution in Cyclodextrin to Placebo in the Treatment of Aspergilloma
NCT00005668 ·Status: COMPLETED ·Phase: PHASE2
-
Interest of Real-time Polymerase Chain Reaction (PCR) in the Diagnosis of Fungal Infections
NCT00876096 ·Status: COMPLETED ·Phase: NA
-
A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects
NCT00940017 ·Status: COMPLETED ·Phase: PHASE4
-
PCR Based Detection of Azole Resistance in A. Fumigatus to Improve Patient Outcome.
NCT03121235 ·Status: COMPLETED
-
Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension in Subjects at High Risk for Invasive Fungal Infections (P05520)
NCT01075984 ·Status: COMPLETED ·Phase: PHASE1
-
Screening Anti-Fungal Exposure in Intensive Care Units
NCT03136926 ·Status: UNKNOWN
-
Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)
NCT00620074 ·Status: TERMINATED ·Phase: PHASE4
-
Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Cryptococcus Neoformans Infection in Patients Not Infected With HIV and Complications Associated With Cryptococcus Neoformans Infection
NCT00001701 ·Status: COMPLETED
-
Early Diagnosis of Aspergillosis in Patients at High Risk of Fungal Infection Caused by Treatment for Hematologic Cancer or Other Disease
NCT00462657 ·Status: UNKNOWN ·Phase: NA
-
An Observational Study of Fungal Biomarkers (MK-0000-089)
NCT00854607 ·Status: COMPLETED
-
Concentrations of Voriconazole in Blood and BAL-fluid After Inhalation and Oral Administration
NCT02396225 ·Status: TERMINATED ·Phase: NA
-
Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems
NCT00238355 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common
NCT00002325 ·Status: COMPLETED ·Phase: NA
-
Early Diagnosis of Invasive Lung Aspergillosis
NCT05860387 ·Status: RECRUITING
-
A Study of Itraconazole in Preventing the Return of Histoplasmosis, a Fungal Infection, in Patients With AIDS
NCT00000992 ·Status: COMPLETED ·Phase: PHASE1